Summary
Which therapy should be used in Type 2 (noninsulin-dependent) diabetic patients with “secondary sulfonylurea failure”, insulin or a combination of sulfonylurea and metformin? To address this question, we have compared the effect of 6 months of insulin therapy twice daily with that of a combination of glibenclamide and metformin in 24 Type 2 diabetic subjects, who no longer responded to treatment with sulfonylureas. Both treatments resulted in an equivalent 30% improvement in mean daily blood glucose (p<0.001), without significant effect on serum lipids. Insulin improved glycaemic control primarily by reducing basal hepatic glucose production (p<0.05), but had no significant effect on peripheral glucose metabolism. The combination of glibenclamide and metformin enhanced significantly total body glucose metabolism (p<0.05), predominantly by stimulating the non-oxidative pathway. Neither insulin nor the combination therapy altered B-cell response to a test meal. Insulin therapy resulted in a 6% increase in body weight, 63% of which was accounted for by increased fat mass. Although body weight was unchanged during sulfonylurea/metformin therapy, lean body mass and energy expenditure decreased significantly (p<0.05). We conclude that insulin and glibenclamide/metformin have different long-term effects on glucose and energy metabolism in Type 2 diabetes.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Groop L, Pelkonen R (1984) Treatment failures: A common problem in the management of patients with type 2 diabetes. Acta Endocrinol 105 [Suppl 262]: 131–135
Groop LC, Pelkonen R, Koskimies S, Bottazzo GF, Doniach D (1986) Secondary failure to treatment with oral antidiabetic agents in non-insulin dependent diabetes. Diabetes Care 9: 129–133
Haupt E, Laube F, Loy H, Schöffling K (1977) Secondary failures in modern therapy of diabetes mellitus with blood glucose lowering sulfonamides. Med Klin 72: 1529–1536
Tattersall RB, Scott AR (1987) When to use insulin in the maturity onset diabetic? Postgrad Med J 63: 859–864
Taylor R (1988) Insulin for the non-insulin dependent? (Editorial) Br Med J 296: 1015–1016J
Peacock I, Tattersall RB (1984) The difficult choice of treatment for poorly controlled maturity onset diabetes: tablets or insulin? Br Med J 288: 1956–1959
Alberti KGMM, Gries A and the European NIDDM Policy Group (1988) Management of non-insulin dependent diabetes mellitus in Europe: a concensus view. Diab Med 5: 275–281
Scott AR, Attenborough Y, Peacock I, Fletcher E, Jeffcoate WJ, Tattersall RB (1988) Comparison of high fibre diets, basal insulin supplements, and flexible insulin treatment for non-insulin dependent (type II) diabetics poorly controlled with sulfonylureas. Br Med J 297: 707–710
MacPherson JN (1988) Insulin for the non-insulin dependent? (letter) Br Med J 296: 1401
Firth RG, Bell PM, Rizza RA (1986) Effects of tolazamide and exogenous insulin on insulin action in patients with non-insulin dependent diabetes mellitus. N Engl J Med 314: 1280–1286
Turner RC and the UK Prospective Study Group. UK Prospective diabetes study. II. Reduction in HbA1c with basal insulin supplement, sulfonylurea, or biguanide therapy in maturity-onset diabetes. A multicenter study. Diabetes 34: 793–798
Holman RR, Steemson J, Turner RC (1987) Sulphonylurea failure in type 2 diabetes: treatment with basal insulin supplement. Diab Med 4: 457–462
Yki-Järvinen H, Nikkilä E, Helve E, Taskinen M-R (1988) Clinical benefits and mechanisms of a sustained response to intermittent insulin therapy in type 2 diabetic patients with secondary drug failure. Am J Med 84: 185–192
DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237: E214-E223
Ferrannini E (1988) The theoretical basis for indirect calorimetry: a review. Metabolism 37: 287–301
Meriläinen PT (1987) Metabolic monitor. Int J Clin Monitor Comput 4: 167–177
Coleman TG, Manning RD Jr, Norman RA Jr, Guyton AC (1972) Dynamics of water-isotope distribution. Am J Physiol 223: 1371–1375
Miles JR, Glasscock J, Aikens J, Gerich J, Haymond M (1983) A microfluorometric method for the determination of free fatty acids in plasma. J Lipid Res 24: 96–99
Cobelli C, Mari A, Ferrannini E (1987) Non-steady state: error analysis of Steele's model and development for glucose kinetics. Am J Physiol 252: E679-E689
Andrews WJ, Vasques B, Nagulesparan M, Klimes I, Foley J, Unger R, Reaven GM (1984) Insulin therapy in obese. Non-insulin dependent diabetes induces improvement in insulin action and secretion that are maintained for two weeks after insulin withdrawal. Diabetes 33: 634–642
Ginsberg H, Rayfield EJ (1981) Effect of insulin therapy on insulin resistance in type II diabetic subjects. Diabetes 30: 739–745
Hidaka H, Nagulesparan M, Klimes I, Clark R, Sasaki H, Aronoff SL, Vasques B, Rubenstein AH, Unger RH (1982) Improvement of insulin secretion but not insulin resistance after short term control of plasma glucose in obese type II diabetics. J Clin Endocrinol Metab 54: 217–222
Scarlett JA, Kolterman OG, Ciaraldi TP, Kao M, Olefsky JM (1983) Insulin treatment reverses the post-receptor defect in adipocyte 3-O-methylglucose transport in type II diabetes mellitus. J Clin Endocrinol Metab 56: 1195–1201
Garvey TW, Olefsky JM, Hamann RF, Kolterman OG (1985) The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 34: 222–234
Randle PJ, Garland PB, Newsholme EA (1963) The glucose fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet I: 785–789
Butterfield WJH, Whichelow MJ (1968) Effect of diet, sulpholnureas and phenformin on peripheral glucose uptake in diabetes and in obesity. Lancet I: 785–788
Lefebvre P, Luyckx A, Mosora F, Lacroix M, Pirnay F (1978) Oxidation of an exogenous glucose load using normally labelled C-13-glucose. Diabetologia 14: 39–45
Nattrass M, Alberti KGMM (1978) Biguanides. Diabetologia 14: 71–74
Corsini GU, Sirigu F, Tagliamonte P, Muntoni S (1974) Effects of biguanides on fatty acid and glucose oxidation in muscle. Pharmacol Res Commun 6: 253–261
Jangaard NO, Pereira JN, Pinson R (1968) Metabolic effects of the biguanides and possible mechanism of action. Diabetes 17: 96–104
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Groop, L., Widén, E., Franssila-Kallunki, A. et al. Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 32, 599–605 (1989). https://doi.org/10.1007/BF00285334
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00285334